Stockholm, 2017-09-15 08:00 CEST (GLOBE NEWSWIRE) --
PledPharma today announced that Michaela Gertz has decided to leave the company after seven years as Chief Financial Officer.
Michaela Gertz, part of PledPharma’s Management Team, has been employed since 2010. She will leave her position in December 2017.
"PledPharma has undergone a growth journey from a project in the early clinical phase to a company with two projects in clinical development of which one is heading into registration studies. Michaela has been an important part of the management team that built PledPharma and I would like to thank her for her valuable contributions and wishing her all the best in her future career, "says PledPharma’s CEO Nicklas Westerholm.
"It has been exiting and developing to take part in and contribute to PledPharmas's journey for seven years, not least in the execution of the company's IPO. I now look forward to apply my experience to a new exciting challenge.” Says PledPharma’s CFO Michaela Gertz
For more information, please contact:
Nicklas Westerholm, CEO, phone: +46 73 354 20 62
Nicklas.westerholm@pledpharma.se
Michaela Gertz, CFO, phone: +46 709 26 17 75
Michaela.gertz@pledpharma.se
About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued development. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see www.pledpharma.se
